Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SYS6010 versus docetaxel in previously treated driver-negative non-squamous NSCLC
CTR20260700Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CPO301 in non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260700.